Literature DB >> 3429444

Purification of human liver cytochrome P-450 catalyzing testosterone 6 beta-hydroxylation.

S Kawano1, T Kamataki, T Yasumori, Y Yamazoe, R Kato.   

Abstract

Two forms of cytochrome P-450 (P-450 human-1 and P-450 human-2) have been purified from human liver microsomes to electrophoretic homogeneity. P-450 human-1 and P-450 human-2 differ in their apparent molecular weights (52,000 and 56,000, respectively) and Soret peak maxima in the CO-binding reduced difference spectrum (447.6 and 450.3 nm, respectively). In the reconstituted system using rat liver NADPH-cytochrome c (P-450) reductase, P-450 human-2 more effectively oxidized benzo(a)pyrene (80-fold), ethylmorphine (2-fold), and 7-ethoxycoumarin (2-fold) than did P-450 human-1. However, P-450 human-1 showed higher testosterone 6 beta-hydroxylase activity, and the activity was markedly increased by the inclusion of cytochrome b5 or spermine in the reconstituted system. Antibodies raised against P-450 human-1 inhibited more than 80% of microsomal testosterone 6 beta-hydroxylase activity in human liver. Immunoblotting analysis using anti-P-450 human-1 IgG revealed a single immuno-staining band near Mr 52,000 in all human liver samples examined. The amount of immunochemically determined P-450 human-1 varied in parallel with the testosterone 6 beta-hydroxylase activity in human liver. These results indicate that P-450 human-1 is a major form of cytochrome P-450 responsible for microsomal testosterone 6 beta-hydroxylation. Thus, this paper is the first report on human cytochrome P-450 responsible for testosterone 6 beta-hydroxylation, which is the major hydroxylation pathway in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3429444     DOI: 10.1093/oxfordjournals.jbchem.a122081

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  6 in total

1.  Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

Authors:  L M Forrester; C J Henderson; M J Glancey; D J Back; B K Park; S E Ball; N R Kitteringham; A W McLaren; J S Miles; P Skett
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

2.  Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine.

Authors:  S Matsumoto; Y Yamazoe
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

3.  Increased production of mitochondrial reactive oxygen species and reduced adult life span in an insecticide-resistant strain of Anopheles gambiae.

Authors:  D Otali; R J Novak; W Wan; S Bu; D R Moellering; M De Luca
Journal:  Bull Entomol Res       Date:  2014-02-21       Impact factor: 1.750

4.  Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism.

Authors:  P M Shaw; T S Barnes; D Cameron; J Engeset; W T Melvin; G Omar; J C Petrie; W R Rush; C P Snyder; P H Whiting
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

5.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

Authors:  D Sesardic; A R Boobis; B P Murray; S Murray; J Segura; R de la Torre; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

6.  Four forms of cytochrome P-450 in human fetal liver: purification and their capacity to activate promutagens.

Authors:  M Kitada; M Taneda; K Itahashi; T Kamataki
Journal:  Jpn J Cancer Res       Date:  1991-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.